13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002077247
Total reported value
$629.9M
$629.9M
26 檔
27.3%
As reported in its official Q1 2026 Form 13F filing, Trails Edge Capital Partners, LP's tracked investment portfolio stood at $629.9M with 26 total positions.
Trails Edge Capital Partners, LP executed strategic sector rebalancing during Q1 2026, establishing 12 new positions while fully exiting 9 holdings and trimming 5 positions.
In terms of portfolio concentration, the top 5 core holdings (including PCVX, XENE, DFTX) accounted for 27.3% of total reported equity market value during Q1 2026.
Top New Position Initiated
DFTX
市值: $32.9M
Top Position Liquidated / Trimmed
ACAD
前期市值: $37.9M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte Inc | Stock-Other | 8.82% | -8.82% | EXIT | |
| 2 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 8.53% | -4.31% | +7.19% | |
| 3 | DFTX | Definium Therapeutics Inc | Stock-Other | 7.53% | -7.53% | EXIT | |
| 4 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 7.45% | +0.40% | -5.46% | |
| 5 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 7.05% | -2.90% | +946.11% | |
| 6 | NRIX | Nurix Therapeutics Inc | Stock-Other | 6.19% | -0.13% | — | |
| 7 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 5.46% | -2.02% | — | |
| 8 | RCUS | Arcus Biosciences Inc | Stock-Other | 5.19% | -5.19% | EXIT | |
| 9 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 4.71% | +0.65% | — | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.53% | -0.63% | — | |
| 11 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.76% | +0.09% | — | |
| 12 | NGNE | Neurogene Inc | Stock-Other | 3.62% | -0.05% | -0.28% | |
| 13 | IVA | Inventiva SA - Adr | Stock-Other | 3.38% | -1.78% | — | |
| 14 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 3.10% | -0.18% | +30.42% | |
| 15 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.78% | +1.92% | — | |
| 16 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 2.43% | -0.52% | — | |
| 17 | IMVT | Immunovant Inc | Stock-Other | 2.36% | -2.36% | EXIT | |
| 18 | DSGN | Design Therapeutics Inc | Stock-Other | 2.08% | +2.52% | — | |
| 19 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 1.96% | -0.62% | -2.24% | |
| 20 | NERV | Minerva Neurosciences Inc | Stock-Other | 1.96% | -0.71% | — | |
| 21 | PMN | Promis Neurosciences Inc | Stock-Other | 1.62% | -0.46% | — | |
| 22 | ✓ | Stock-Other | 1.55% | +0.09% | — | ||
| 23 | IPSC | Century Therapeutics Inc | Stock-Other | 1.27% | +0.34% | — | |
| 24 | VTVT | Vtv Therapeutics Inc- Cl A | Stock-Other | 1.27% | -0.76% | -39.58% | |
| 25 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.90% | +1.15% | — | |
| 26 | IRD | Opus Genetics Inc | Stock-Other | 0.52% | +1.27% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals Inc | +6.4% | +946.11% | Add |
| 2 | XENE | Xenon Pharmaceuticals Inc | +1.9% | +7.19% | Add |
| 3 | IMVT | Immunovant Inc | +0.9% | +72.40% | Add |
| 4 | PCVX | Vaxcyte Inc | +0.4% | -10.17% | Trim |
| 5 | IVA | Inventiva SA - Adr | +0.3% | — | Unchanged |
| 6 | IKT | Inhibikase Therapeutics Inc | 0% | +30.42% | Add |
| 7 | XFOR | X4 Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 8 | RCUS | Arcus Biosciences Inc | -0.2% | +14.36% | Add |
| 9 | LBRX | Lb Pharmaceuticals Inc | -0.2% | -5.46% | Trim |
| 10 | NGNE | Neurogene Inc | -0.4% | -0.28% | Trim |
| 11 | VTVT | Vtv Therapeutics Inc- Cl A | -1% | -39.58% | Trim |
| 12 | CAMP | Camp4 Therapeutics CORP | -1% | -2.24% | Trim |
| 13 | IMCR | Immunocore Holdings Plc-adr | -1.1% | — | Unchanged |
| 14 | NRIX | Nurix Therapeutics Inc | -2% | — | Unchanged |
| 15 | ACAD | Acadia Pharmaceuticals Inc | — | EXIT | Sold out |
| 16 | BRD1EUR | Mind Medicine Mindmed Inc | — | EXIT | Sold out |
| 17 | DFTX | Definium Therapeutics Inc | — | NEW | New buy |
| 18 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 19 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 20 | TYRA | Tyra Biosciences Inc | — | EXIT | Sold out |
| 21 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 22 | AM6 | Amicus Therapeutics Inc | — | EXIT | Sold out |
| 23 | APGE | Apogee Therapeutics Inc | — | EXIT | Sold out |
| 24 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 25 | 430 | Terns Pharmaceuticals Inc | — | EXIT | Sold out |
| 26 | MBX | Mbx Biosciences Inc | — | EXIT | Sold out |
| 27 | DSGN | Design Therapeutics Inc | — | NEW | New buy |
| 28 | NERV | Minerva Neurosciences Inc | — | NEW | New buy |
| 29 | CMPX | Compass Therapeutics Inc | — | EXIT | Sold out |
| 30 | PMN | Promis Neurosciences Inc | — | NEW | New buy |
| 31 | ✓ | — | NEW | New buy | |
| 32 | IPSC | Century Therapeutics Inc | — | NEW | New buy |
| 33 | FTH | Faeth Therapeutics Inc | — | NEW | New buy |
| 34 | ELVN | Enliven Therapeutics Inc | — | EXIT | Sold out |
| 35 | IRD | Opus Genetics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Trails Edge Capital Partners, LP reported a total U.S. public equity portfolio value of $629.9M across 26 disclosed positions in Q1 2026.
During Q1 2026, Trails Edge Capital Partners, LP's top holdings by market value included PCVX (8.8%)、XENE (8.5%)、DFTX (7.5%). The largest single position, PCVX, represented 8.8% of total portfolio value.
In Q1 2026, Trails Edge Capital Partners, LP made 31 total portfolio adjustments, initiating 12 new buys, adding to 5 positions, trimming 5 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.